AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly...

{
  "signal_id": "8fd1a8f3-e81c-708c-508f-ab1a82b9f975",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-05T18:54:00+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/abbvie-and-genmab-announce-epcoritamab-in-combination-with-r-chop-demonstrates-significant-improvement-in-progression-free-survival-versus-r-chop-in-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-302898795.html",
    "title": "AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma",
    "excerpt": "NORTH CHICAGO, Ill. and COPENHAGEN, Denmark , Oct. 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV ) and Genmab A/S (Nasdaq: GMAB ) today announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously , in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 2 to 5. The trial demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in DLBCL patients with an IPI score of 2 to 5. The risk of disease progression or death was reduced by 51% (HR 0.49 [95% CI 0.36, 0.67]; p-value < 0.0001). The safety profile of epcoritamab when administered in combination with standard of care R-CHOP was generally well tolerated and consistent with the previously reported safety profiles of the individual agents (epcoritamab and R-CHOP). \"DLBCL is an aggressive disease and the need to advance treatment options is critical. These positive topline results suggest that epcoritamab combined with R-CHOP could offer a potential new standard of care in newly diagnosed DLBCL patients,\" said Daejin Abidoye, MD...",
    "product": "epcoritamab",
    "summary": "AbbVie and Genmab announced positive topline results from a Phase 3 trial of their jointly developed drug, epcoritamab, in combination with R-CHOP, for treating newly diagnosed diffuse large B-cell lymphoma (DLBCL).",
    "planning": false,
    "confidence": 0.95,
    "product_data": {
      "name": "epcoritamab",
      "full_text": "epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-10-05T18:54:00Z",
    "effective_date": "2026-10-05",
    "article_sentence": "AbbVie (NYSE: ABBV ) and Genmab A/S (Nasdaq: GMAB ) today announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously , in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 2 to 5.",
    "related_company_name": "Genmab",
    "related_company_domain": "genmab.com"
  }
}

curl https://signals.autobound.ai/v1/signals/8fd1a8f3-e81c-708c-508f-ab1a82b9f975 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'